Literature DB >> 1979930

Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids.

K A Sutters1, C Miaskowski, Y O Taiwo, J D Levine.   

Abstract

This study evaluated the effects of intrathecal administration of a low-analgesic dose of the selective mu-agonist DAMGO co-administered with sequentially increasing doses of either the selective delta-agonist DPDPE or the selective kappa-agonist, U50,488H on mechanical nociceptive thresholds in the rat. Potent analgesic synergy was observed with both combinations. Since an elevation in nociceptive threshold can result from motor deficits, as well as true analgesia, we also evaluated the effects of the combination regimens on motor coordination using a rotarod apparatus. The combination regimens produced significantly less motor deficits than those observed when DPDPE and U50,488H were administered as single agents. These findings of enhanced analgesia with decreased motor side-effects associated with administration of fixed mu/delta or mu/kappa combinations suggest that co-administration of opiates that act at different receptors may constitute a superior approach to the treatment of pain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979930     DOI: 10.1016/0006-8993(90)91297-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats.

Authors:  Audrey Normandin; Philippe Luccarini; Jean-Louis Molat; Louis Gendron; Radhouane Dallel
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 3.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.

Authors:  Ariana C Brice-Tutt; Lisa L Wilson; Shainnel O Eans; Heather M Stacy; Chloe A Simons; Grant G Simpson; Jeremy S Coleman; Michael J Ferracane; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2020-07-16       Impact factor: 8.739

5.  BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.

Authors:  Ning Li; Zheng-Lan Han; Zi-Long Wang; Yan-Hong Xing; Yu-Long Sun; Xu-Hui Li; Jing-Jing Song; Ting Zhang; Run Zhang; Meng-Na Zhang; Biao Xu; Quan Fang; Rui Wang
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

Review 6.  Intracerebroventricular opioids for intractable pain.

Authors:  Robert B Raffa; Joseph V Pergolizzi
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

7.  In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Authors:  John J Lowery; Tyler J Raymond; Denise Giuvelis; Jean M Bidlack; Robin Polt; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2010-11-30       Impact factor: 4.030

8.  Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.

Authors:  Vanessa Minervini; Hannah Y Lu; Jahnavi Padarti; Daniela C Osteicoechea; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

9.  Evaluation of the interaction of mu and kappa opioid agonists on locomotor behavior in the horse.

Authors:  K R Mama; P J Pascoe; E P Steffey
Journal:  Can J Vet Res       Date:  1993-04       Impact factor: 1.310

10.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.